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Edited by Beat ImhofAbstract We isolated mouse embryo ﬁbroblasts (MEFs) from
N-acetylglucosaminyltransferase Va (GnT-Va) knockout mice
and studied the eﬀects of loss of expression of GnT-Va on aspar-
agine-linked glycans (N-glycan) synthesis and the gene expression
of groups of glycosyltransferases and galectins. Loss of GnT-Va
expression caused aberrant expression of several N-glycan struc-
tures, including N-linked b(1,6) branching, poly-N-lactosamine,
bisecting N-acetylglucosamine (GlcNAc) and sialic acid. Using
quantitative reverse transcriptase-PCR (qRT-PCR), altered gene
expression of several groups of glycosyltransferases and galectins
was observed in GnT-Va null MEFs, supporting the observed
changes inN-glycan structures. These results suggest that genetic
disruption of GnT-Va ultimately resulted in altered MEFs gene
expression and decreased tumor progression associated with loss
of GnT-Va observed may result in part from a combination of
eﬀects from these altered gene expressions.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Many studies show that alterations in N-linked oligosaccha-
rides of tumor cells are associated with tumorigenesis, progres-
sion and metastasis. N-linked b(1,6)-N-acetylglucosamine
(GlcNAc) synthesized by N-acetylglucosaminyltransferase
Va (GnT-Va or Mgat5) is one of the more common glycans
up-regulated during malignant transformation [1]. Studies
have proposed a close relationship between increased GnT-
Va activity and its glycan products with enhanced cell invasive-
ness, and in some cases metastatic potential [2–4]. In GnT-Va
deﬁcient mice, the progression of mammary tumors induced by
polyoma middle T oncoprotein (PyMT) expression was signif-
icantly suppressed [5].
It is well-documented that modiﬁcation of cell surface adhe-
sion molecules and growth factor receptors by GnT-Va isAbbreviations: MEFs, mouse embryo ﬁbroblasts; GnT-Va, N-acetyl-
glucosaminyltransferase Va; GlcNAc, N-acetylglucosamine; N-glycan,
asparagine-linked glycans; L-PHA, leucoagglutinating phytohemag-
glutinin; qRT-PCR, quantitative reverse transcriptase-PCR
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types [2,6–8]. A recent report showed that aberrant expression
of GnT-Va caused altered expression of surface sialyl Lewis X
(Slex), a sialylated fucose-containing antigen related to tumor
metastasis, by changing the expression of Slex biosynthesis-re-
lated glycosyltransferases [9]. We found that deletion of GnT-
Va in mouse embryo ﬁbroblasts (MEFs) causes up-regulation
of b1 integrin transcripts, which consequently increased ﬁbro-
nectin-induced cell adhesion and reduced cell motility [10].
These results suggest that aberrant glycosylation caused by
GnT-Va inhibition might regulate the gene expression of other
proteins.
To further elucidate the molecular mechanisms whereby
GnT-Va-modiﬁed asparagine-linked glycans (N-glycans) may
aﬀect tumor invasiveness-related phenotypes in MEFs and
mammary tumor cells [7,10], we explored the eﬀect of genetic
disruption of GnT-Va on the expression of other glycosyl-
transferase and galectin transcripts. We report here, for the
ﬁrst time, that the genetically targeted deletion of GnT-Va
causes the altered gene expression of several glycosyltransfer-
ases and galectins in MEFs using a newly developed qRT-
PCR transcript analysis platform [11]. We speculate that some
of the inhibited invasiveness-related phenotypes in MEFs
caused by deletion of GnT-Va may result, at least in part, from
the combination of altered expression of these glycosyltansfe-
rases and/or galectins.2. Materials and methods
2.1. Antibodies and chemicals
Antibodies against galectin-1 and galectin-3, ERK1/2, and HRP-la-
beled anti-rabbit IgG and anti-mouse IgG were from Santa Cruz Bio-
technology. Monoclonal antibody against b1 integrin was a product of
BD Biosciences. OL.28 anti-polysialic acid antibody was kind gift from
Dr. Karen Colley. Streptavidin–HRP and streptavidin–agarose were
obtained from Rockland. WGA–agarose and biotinylated lectins were
products of Vector Laboratories.
2.2. Isolation of MEFs
Mouse embryo ﬁbroblasts (MEFs) were isolated from E13.5 em-
bryos from heterozygous GnT-Va knock-out mice mating, and the
genotype of MEFs was identiﬁed by PCR analysis using genomic
DNA as described earlier [6].
2.3. GnT-V activity assay
The assay of GnT-V activity was performed using a synthetic trisac-
charide acceptor as previously described [2].blished by Elsevier B.V. All rights reserved.
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MEFs were harvested, re-suspended in DMEM growth medium and
seeded into six-well plates with 2–3 · 105 cells/well. Assay of cell
growth and survival was performed as previously described [12].
2.5. N-Glycan analysis by HPLC
About 100 mg liver tissue were homogenized and N-glycans were re-
leased from glycoproteins by digestion of the sample with 10 U PNG-
ase-F at 37 C overnight. Released glycans were ﬂuorescently labeled
with 2-aminopyridine (2-AP) as previously reported [13]. Excess 2-
AP was removed by gel ﬁltration using a Sephadex G-15 column
(1 · 50 cm) and the 2-AP labeled glycans were fractionated on a
4.6 · 250 mm TSK Amide-80 column as described previously [14].
2.6. Immuno- and lectin-blotting and lectin pull-down
Cells were harvested, lysed, and 20 lg of protein was used for immu-
no- and lectin-blotting [10]. For some experiments, cell lysates were
boiled in denaturing buﬀer containing 0.1% SDS and 1 mM DTT for
5 min and treated with PNGase-F at 37 C overnight before they were
subjected to lectin-blotting. For lectin pull-down experiments, 500 lg of
protein was incubated with 5 lg of a biotinylated lectin or lectin–aga-
rose at 4 C overnight, followed by addition of agarose–streptavidin.
2.7. Quantitative RT-PCR analysis
Primer pairs for investigated genes and control genes were designed
within a single exon using conditions described in Nairn et al. [11] and
listed in Table 1. Primers were validated with respect to primer eﬃ-
ciency and single product detection [11].
The RNeasy kit (Qiagen) was used to isolate total RNA fromMEFs.
One microgram of total RNA was used for a 20 ll cDNA synthesis
reaction using the SuperScript III First-Strand Synthesis System (Invit-
rogen). Reactions were assembled as described [11]. The control gene,
Ribosomal Protein L4 (RPL4, NM_024212) was included on each
plate to control for run variation and to normalize individual gene
expression.
Triplicate cycle threshold (Ct) values for each gene were averaged
and the standard deviation was calculated. Samples that resulted in a
standard deviation of >0.5 Ct units were re-run until values with stan-
dard deviations within an acceptable range were acquired. The loga-
rithmic average Ct value for each gene and the control gene was
converted to a linear value using the conversion: 2Ct. Converted val-
ues were normalized to RPL4 by dividing the individual gene value by
the control gene value. Normalized values were scaled so that genes
that were below the level of detection were given a value of 1 · 106
and this value was used as the lower limit on histograms. Following
normalization and scaling, expression data is reported as the relative
transcript abundance for each gene assayed. Error bars represent one
standard deviation from the mean value.3. Results
3.1. Characterization of MEFs from embryos
Compared with wild-type, GnT-Va activity was absent in
major tissues from GnT-Va null mice (Fig. 1A). Analysis of
2-AP labeled N-linked glycans by HPLC indicated a complete
disappearance of the peak representing the asialo tetra-anten-
nary N-glycan in liver (Fig. 1B), indicating the disappearance
of N-linked b(1,6) branching caused by the absence of GnT-
Va. We have previously observed that GnT-Va null MEFs dis-
played undetectable GnT-Va activity and lost the typical mor-
phology of a ﬁbroblast when compared to wild-type cells [10].
GnT-Va deﬁcient (KO) and wild-type (WT) MEFs were iso-
lated from 13.5 days embryos. Cell growth in serum-containing
medium (Fig. 1C, top) and cell viability in serum-free medium
(Fig. 1C, bottom) were measured. GnT-Va null MEFs showed
signiﬁcant decreases in both cell growth and cell survival indi-
cating that the rate of proliferation of MEFs was aﬀected by
deletion of GnT-Va.3.2. Aberrant N-glycan expressions in GnT-Va deﬁcient MEFs
To further study N-glycans changes caused by deletion of
GnT-Va in MEFs, lectin-blotting and -precipitation experi-
ments were performed. The binding of not only leucoaggluti-
nating phytohemagglutinin (L-PHA), but also DSA was
extensively suppressed in GnT-Va null MEFs (Fig. 2A),
indicating the suppression of both b(1,6) branched and
poly-N-acetyllactosamine structures, respectively. This result
conﬁrmed our observation that poly-N-acetyllactosamine is
synthesized preferentially on N-glycans expressing the b(1,6)
branch [6]. After treatment of cell lysates with PNGase-F,
most binding of L-PHA and DSA were abolished, conﬁrming
these bound N-linked glycans. The expression of either high
mannose or biantennary N-linked oligosaccharides was not
signiﬁcantly aﬀected by deletion of GnT-Va, as detected by
ConA binding (Fig. 2A). Increased E-PHA binding was ob-
served for a few, but not all proteins from GnT-Va knockout
cells (indicated as arrows, Fig. 2A), indicating selective in-
creased expression of bisecting N-linked GlcNAc. a(1,3)
fucosylation did not appear to be aﬀected, as detected by Lo-
tus agglutinin (LTA) binding (data not shown). To study the
eﬀect of GnT-Va knockout on sialylation, we used WGA–
agarose ﬁrst to pull-down sialic acid-containing glycoproteins,
followed by blotting with MAA, SNA and anti-polysialic acid
antibody (OL.28), respectively. Surprisingly, a(2,6)-sialylation
detected by Sambucus nigra agglutinin (SNA) was increased,
while a(2,3)-sialylation and a(2,8)-polysialylation, detected
by Maakia ameurinsin agglutinin (MAA) binding and
OL.28, respectively, were dramatically decreased in GnT-Va
null MEFs (Fig. 2B). Consistent with these ﬁndings, b1 inte-
grin, an abundant surface proteins on MEFs, showed unde-
tectable expression of b(1,6) branching in GnT-Va null
MEFs, but a signiﬁcant increase of a(2,6)-sialylation, com-
pared to wild-type cells (Fig. 2C). These results indicate that
deletion of GnT-Va caused signiﬁcant changes in not only
b(1,6) branching, but also other N-glycan expression in
MEFs.3.3. Altered gene expression of glycosyltransferses in GnT-Va
null MEFs
To begin a study of the mechanisms by which the diﬀerentN-
glycan structures were changed in GnT-Va deﬁcient MEFs,
transcript levels of relevant groups of glycosyltransferases,
listed in Table 2, were detected by qRT-PCR using total
RNA isolated from MEFs. As shown in Fig. 3 and Table 2, al-
tered gene expression patterns were observed for several groups
of glycosyltransferases after deletion of GnT-Va. The expres-
sion of 7N-acetylglucosaminyltransferase (GnT) transcripts
was determined (Fig. 3A and Table 2). The expression of
GnT-I, GnT-III and GnT-IVb was signiﬁcantly increased in
GnT-Va null cells. GnT-Va was detected in wild-type but not
in GnT-Va null cells. GnT-Vb was not detected in either
wild-type or GnT-Va null cells. Two other groups of glycosyl-
transferases that regulate the initiation and extension ofN-acet-
yllactosamine chains on glycoproteins and glycolipids, b(1,3)-
N-acetylglucosaminyltransferases (b3GnT) and b(1,4)galac-
tosyltransferases (b4GalT), were aﬀected by either up- or
down-regulation after deletion of GnT-Va. Among them,
b3GnT-III, V and VII were extremely reduced in GnT-Va null
MEFs, while b3GnT-I and II and b4GalT-I, II, VI, were in-
creased (Fig. 3B and Table 2).
Table 1
Sequences of primers used in qRT-PCR
Gene Abbreviation Accession number Forward primer (5 0–3 0) Reverse primer (50–30)
Mannoside acetylglucosaminyltransferase 1 Mgat1 NM_010794 CCCTTCACCCAGTTGGACCTG GCACCATAGACCTGGGCGAG
Mannoside acetylglucosaminyltransferase 2 Mgat2 NM_146035 TGCTGGAGACTGTGGTATGC ACTCAATTTGGGCACTCTGG
Mannoside acetylglucosaminyltransferase Mgat3 NM_010795 GCGTGATGGTGTGCTGTTCC ACAGGGACTTCCGCATGTGG
Mannoside acetylglucosaminyltransferase 4, isoenzyme A Mgat4a NM_173870 GCGACAGACAGAAGGCAAACC CCGACAGAGACGAGTGTAGGC
Mannoside acetylglucosaminyltransferase 4, isoenzyme B Mgat4b NM_145926 AGGTGACGTGGTGGACATTT GCTTCAGGCTCTCTTGCTCA
Mannoside N-acetylglucosaminyltransferase Va Mgat5a NM_145128 CCCTGGAAGTTGTCCTCTCA TCCTCTGCCAGTGCCTTAAT
Mannoside acetylglucosaminyltransferase 5, isoenzyme B Mgat5b NM_172948 TGCCCTGTGACAGCACTGAG GTAGGTAGCACTCTTGGCCGG
Glucosaminyl (N-acetyl) transferase 1, core2 Gcnt1 NM_173442 CGAAGGCCATGTTTCCAACGG TCCGAAGACGCACACAGAGC
Glucosaminyltransferase, I-branching enzyme Gcnt2 NM_008105 CGGTTGATTTGCTCCATTG TATTGAGCGTCACCCAGAAAT
Glucosaminyl (N-acetyl) transferase 3, mucin type Gcnt3 NM_028087 ACCCAGGCTCTGCTGAATAA AGGTAGTCGGCCTCTGTGAA
Beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) B3gat1 NM_029792 ACCGTGACATCGTGGAAGTGG GGATGGTGGGCAGCGTGTC
Beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S) B3gat2 NM_172124 CACACTCGGACAGAGAAGGTC CCTCAATGTTCACTGTGTCCA
UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 1 B4galt1 NM_022305 GGCGTCACCCTCGTCTATTA GCCCTGCAGTGTAGAGGAGA
UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 2 B4galt2 NM_017377 GCCGCTATTCTCCACCCGAC GGTGCTCCCGGTGTCTAAAGG
UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 3 B4galt3 NM_020579 TGAAGAATGGGACTGCTTGTT TCGCACACATACAGGTTATGG
UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 4 B4galt4 NM_019804 GACGTGGACCTGGTGCCTG GTTCCGGCCCACCACCAAG
UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 5 B4galt5 NM_019835 CGGTCCTCCTGAGACACCT CACATAGAAGGCGAACTGCA
UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 6 B4galt6 NM_019737 CGGCACACAACCATTCAAT ATCACACAGTCCCAGGCTCT
Xylosylprotein beta1,4-galactosyltransferase, polypeptide 7 B4galt7 NM_146045 CGGGCAGCACTCATCAATGTG GAGGGAGCAGGTCCACATCG
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 B3gnt1 NM_175383 GGAGAGCTTGCTGAGACCTG CCTTTCCTCCAGCCACATAA
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 B3gnt2 NM_016888 TTAGGTGGGTGAGCACTTCC GATGGGTGTTCACAAACACG
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 B3gnt3 NM_028189 TCTTCCTTGTGGGCTCAGAC GTATTTCTGCGCTTCCAGCT
Beta-1,3-N-acetylglucosaminyltransferase-4 B3gnt4 NM_198611 CCAGCCGTCATCGCCTCTTC CACACTCCGAAGGCTCCAGC
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 B3gnt5 NM_052993 GCAAGGCATTCAGATGACAA ATGTTGGCTGGAATCTGCAT
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 B3gnt7 NM_145222 GGGCCACGAATGGGAGTCAG TCCTCTTGCTTGGAGGCTGTG
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 B3gnt8 NM_146184 CGGCGCTATGGTGACCTACTG TCAGCAGCAGCAGGTCCTTG
Sialyltransferase 4A (beta-galactosidase alpha-2,3-sialytransferase) St3gal1 NM_009177 TCCTACAACTGCACAGCGTCG TGTTTCGCCTGGTGCCTGG
Sialyltransferase 5 (N-acetyllacosaminide alpha 2,3-sialyltransferase) St3gal2 NM_178048 GCTCTCTTCGGGTGTGGTTCC ATGCTGTGGTGCGAGTAGGTG
Sialyltransferase 6 (N-acetyllacosaminide alpha 2,3-sialyltransferase) St3gal3 NM_009176 CAGCAAGAAACCCAGACCAT ATGAATGGCTCCGTCCATAG
Sialyltransferase 4C (beta-galactosidase alpha-2,3-sialytransferase) St3gal4 NM_009178 GCTCCTGTGGCTGGCTACG GGGTCAAAGTGGGCCGACTC
Sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase) St3gal5 NM_011375 AGCCTCTTGGATATGCTGCCC CGTTCCCAACAACCACACAGC
Sialyltransferase 10 (alpha-2,3-sialyltransferase VI) St3gal6 NM_018784 ATGGTGGCATTCCCGTAGTA AAGTGCACCTCGCTGGTTT
Sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase) St6gal1 NM_145933 TGCGTGTGGAAGAAAGGGAGC CTCCTGGCTCTTCGGCATCTG
Beta-galactoside alpha-2,6-sialyltransferase II (ST6GalII-pending) St6gal2 NM_172829 AGCAATCCTGCGGCACCTATG CCGCTGCTTGCCCTGTAGAG
Sialyltransferase 8A (alpha-2,8-sialytransferase) St8sia1 NM_011374 TTTGGTGAGTGCAGCCTTGGG TGCATGTTCACCGAGAAGGGC
Sialyltransferase 8B (alpha-2,8-sialytransferase) St8sia2, STX NM_009181 CGGCCTCAATGGGAGCATCC AGCATTGACCCACTCCACACG
Sialyltransferase 8C (alpha-2,8-sialytransferase) St8sia3 NM_009182 TCCAACCACAGCACAAACAT AATAACTTCCGGTCCCTGCT
Sialyltransferase 8D (alpha-2,8-sialytransferase) St8sia4, PST NM_009183 CCTAGCACAGGTCTCCTCATG GGAAATGGCCAGAATCCATA
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 St8sia5 NM_153124 CCTGGTATCCTTCCGAGTCA TGCGGGTGGAAGAAGTAGAC
Alpha-2,8-sialyltransferase VI St8sia6 NM_145838 GTTGATGGAGGGAAGCAGAG GGGCTCCAGAGTGTCTTCAG
Lectin, galactose binding, soluble 1 Lgals1 NM_008495 CAGCAACAACCTGTGCCTAC ACAATGGTGTTGGCGTCTC
Lectin, galactose binding, soluble 2 Lgals2 NM_025622 AAGAAACCCTCAACCTGCATT GGCCACCTTCACTGGTGTTA
Lectin, galactose binding, soluble 3 Lgals3 NM_010705 CCTTGCCTGGAGGAGTCAT TGTTTGCGTTGGGTTTCAC
Lectin, galactose binding, soluble 4 Lgals4 NM_010706 TCGTCCGGAGACATAGCTTT CATAAAGCTGTTGCGAACCA
Lectin, galactose binding, soluble 6 Lgals6 NM_010707 CAACTTCTCCCATCGGTTCC TGAGGTCACCATTGATCTCCA
Lectin, galactose binding, soluble 7 Lgals7 NM_008496 CTATGCGGTGAGGAGCAAG ACAACCTCGGAAGTGTCCAG
Lectin, galactose binding, soluble 8 Lgals8 NM_018886 GACTTTCAGCTGGGCAACA TGAACCGAGGGTTAAAGTGG
Lectin, galactose binding, soluble 9 Lgals9 NM_010708 CCGTTTCAATGAGAATGCTG AGCAGACTTCGCTCTTCCTG
Lectin, galactose binding, soluble 12 Lgals12 NM_019516 TCAGCCAGATGTTGCCTTC GTGGGTGTTGCAGATGACAT
Ribosomal Protein L4a RPL4 NM_024212 GACAGCCCTATGCCGTCAGTG GCCACAGCTCTGCCAGTACC
aNormalization control gene.
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Fig. 1. Isolation of mouse embryonic ﬁbroblasts (MEFs) from GnT-Va null mice. (A) Mouse tissues were collected, homogenized, and GnT-Va
activities determined. (B) N-Glycans were released from liver tissue and ﬂuorescently labeled with 2-PA, N-glycan structures were characterized by
HPLC. N-glycan structural symbol: tri-antennary N-glycan (top) and tetra-antennary N-glycan (bottom). (C) (top) growth curve of MEFs cultured
in serum-containing medium; (bottom) viability of cells cultured in serum-free medium. Each point represents the mean value of cell number from
three independent experiments. WB: Western blotting.
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observed within another group of glycosyltransferases, the sial-
yltransferases (ST), which consist of three speciﬁc subfamilies
based on their substrate speciﬁcity and type of sialyl linkages
of the products (a2,3, a2,6 and a2,8). The a(2,3)sialyltransfe-
rases (ST3Gals) catalyze the formation of a(2,3) sialylated
structures and play an essential role in performing the sialyla-
tion of LeX structure (sLex). As shown in Fig. 3C, the expres-
sion of ST3Gal-I, III and V were increased, while ST3Gal-IV
and VI were reduced after deletion of GnT-Va. Decreased
expression of ST3Gal-IV and VI could result in the observed
signiﬁcant inhibition of the biosynthesis of a(2,3) sialylated
structures (Fig. 2B). The a(2,6) sialyltransferases (ST6Gals)
are another group of the sialyltransferase family and generate
a(2,6)-linked sialylated structures. A signiﬁcant increase in
ST6Gal-I transcripts was found in GnT-Va null cells, which
was consistent with N-glycan changes detected by SNA bind-
ing (Fig. 2B). A terminal linear homopolymer of a(2,8) linked
sialic acids is another important form of sialylation catalyzed
by a(2,8) sialyltransferase (ST8sia), which participates in neu-ral development [15]. Two major ST8sia which are responsible
for the biosynthesis of polysialylation (PSA) are ST8sia-II/
STX and ST8sia-IV/PST [16,17]. Interestingly, the expression
of ST8sia-II/STX was extremely decreased in GnT-Va null
MEFs, which was consistent with reduced polysialylation
determined by anti-polysialylation antibody binding, whereas
the level of ST8sia-IV/PST was undetectable (Fig. 3C). A large
decrease of ST8sia-V was also observed in null MEFs,
although its expression level was, however, very low.
In addition, deletion of GnT-Va also caused changes in
some glycosyltransferase transcripts responsible for the bio-
synthesis of O-glycans. The expression of core2GnT-I, which
catalyzes the formation of the branched core2 and core4 O-
glycans [18] was reduced (Fig. 3D), while core2GnT-II and
III expression were very low and undetectable, respectively,
in MEFs.
3.4. Altered gene expression of galectins in GnT-Va null MEFs
Galectins (Gal) are a family of carbohydrate-binding
proteins with an aﬃnity for b-galactosides [19]. To date, 15
Fig. 2. Deletion of GnT-Va caused altered N-glycan expression. (A) N-Glycan structures were detected using cell lysates (with or without PNGase-F
pre-treatment) by lectin-blotting. *Non-speciﬁc binding. The small arrows indicated increased binding proteins. L-PHA, leucoagglutinating
phytohemagglutinin; DSA, D. stramonium agglutinin; E-PHA, erythroagglutinating phytohemagglutinin; ConA, concanavalin A; PNGF, PNGase-
F; WB: Western blotting. (B) Glycoproteins were lectin precipitated (LP) from cell lysates using WGA–agarose, followed by blotting with lectins and
antibodies. Anti-b1 integrin was used for loading control. WGA, wheat germ agglutinin; MAA, M. amurensis agglutinin; SNA, S. nigra agglutinin;
OL.28, anti-polysialic acid antibody. (C) Cell lysates were subjected to L-PHA and SNA precipitation (LP), respectively, followed by SDS–PAGE,
blotting, and detection using antibody against b1 integrin (top two panels). Immunoblots of cell lysates with anti-b1 integrin were performed as
control to conﬁrm amount of precipitated b1 integrin in both cell lines (bottom panel).
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if deletion of GnT-Va causes altered expression of galectins
in MEFs, the transcript expression pattern of galectins was
studied. The transcript abundance of Gal-1, Gal-2, Gal-3
and Gal-9 was increased to diﬀerent degrees, while tran-
script levels of Gal-4, Gal-6 and Gal-8 were reduced in
GnT-Va null MEFs (Fig. 4A and Table 3). Consistent with
the transcript expression, Western blotting showed increased
protein expression of both Gal-1 and Gal-3 (Fig. 4B), the
two most abundant galectins in mouse, in GnT-Va null
MEFs.4. Discussion
In the present study, we isolated MEFs from GnT-Va
knockout mice and explored the eﬀects of genetic disruption
of one glycosyltransferase, GnT-Va, on the gene expressions
of other glycosyltransferases and galectins. We showed that
deletion of GnT-Va had marked eﬀects on MEFs growth on
plastic and cell survival. Supporting these observation, the
phosphorylation of both ERK and PKB was signiﬁcantly
inhibited in GnT-Va null mammary tumor cells and MEFs[5,7], suggesting a possible role of GnT-Va in regulating cell
growth and apoptosis.
Consistent with undetectable activity of GnT-Va in the null
MEFs, we found that the expression of b(1,6) branched oligo-
saccharides and poly-N-acetyllactosamine, determined by L-
PHA and DSA binding, respectively, were almost entirely
inhibited after deletion of GnT-Va in MEFs. Interestingly, ‘‘bi-
sected’’ N-linked glycans produced by GnT-III, and recog-
nized by E-PHA binding, were increased in GnT-Va null
MEFs, consistent with the possible competition between
GnT-III and GnT-Va for biantennary substrates during glyco-
protein biosynthesis in the Golgi [20]. Of note, signiﬁcant de-
creases in a(2,3) sialylation and a(2,8) polysialylation were
observed after deletion of GnT-Va, reﬂecting changes in enzy-
matic activity of both a(2,3) sialyltransferases and a(2,8) poly-
sialyltransferases. A signiﬁcant increase in a(2,6) sialylation,
detected by SNA binding was observed in GnT-Va null cells,
indicating increased activity of ST6Gal resulting from deletion
of GnT-Va. This result was consistent with our recent ﬁnding
that knockdown of GnT-Va by siRNA led to increased a(2,6)
sialylation expression on cell surface EGFR in human mam-
mary tumor cells [8]. Supporting these ﬁndings, a recent report
[21] demonstrated that targeted deletion of Mgat4a also caused
Table 2
Altered gene expression proﬁle of glycosyltransferases in GnT-Va null
MEFs
Gene WT (mean)a KO (mean)a Ratio (WT/KO)
Mgat1 0.027673 0.046369 0.596791
Mgat2 0.108606 0.124820 0.870100
Mgat3 0.004548 0.007684 0.591858
Mgat4a 0.001230 0.000953 1.290909
Mgat4b 0.029364 0.063232 0.464377
Mgat5a 0.004605 0.000001 4605.313126
Mgat5b 0.000001 0.000001 1.000000
Gcnt1 0.004553 0.002759 1.650467
Gcnt2 0.000001 0.000001 1.000000
Gcnt3 0.000001 0.000001 1.000000
B4galt1 0.019953 0.032838 0.607618
B4galt2 0.012594 0.024487 0.514288
B4galt3 0.009568 0.008144 1.174870
B4galt4 0.005826 0.003895 1.495915
B4galt5 0.005516 0.006892 0.800403
B4galt6 0.001240 0.003591 0.345244
B4galt7 0.009342 0.010353 0.902375
B3gnt1 0.002855 0.004278 0.667305
B3gnt2 0.013662 0.020811 0.656500
B3gnt3 0.000110 0.000001 110.138458
B3gnt4 0.000144 0.000184 0.781529
B3gnt5 0.003916 0.000536 7.311063
B3gnt7 0.000098 0.000027 3.681326
B3gnt8 0.000195 0.000205 0.948217
St3gal1 0.001698 0.002569 0.660952
St3gal2 0.057057 0.070288 0.811768
St3gal3 0.021313 0.036801 0.579139
St3gal4 0.023461 0.015987 1.467521
St3gal5 0.044011 0.077479 0.568035
St3gal6 0.000038 0.000026 1.446651
St6gal1 0.003774 0.007324 0.515373
St6gal2 0.000001 0.000001 1.000000
St8sia1 0.000006 0.000056 0.103812
St8sia2, STX 0.003064 0.000116 26.359330
St8sia3 0.000001 0.000001 1.000000
St8sia4, PST 0.000001 0.000001 1.000000
St8sia5 0.000078 0.000003 23.826403
St8sia6 0.000001 0.000003 0.376690
0.000001 = below the level of detection.
The ratio is a simple division of the data for WT and KO for a speciﬁc
gene.
aRelative transcript abundance (as described in Section 2).
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islet b cells. These results suggested that genetic disruption of
one glycosyltransferase could aﬀect others changes in glycan
expression.
To further investigate if altered N-glycan structures resulted
from changes in gene expression of diﬀerent glycosyltrans-
ferases, transcript levels of diﬀerent families of glycosyl-
transferases were evaluated using qRT-PCR. In the family of
GnTs, several transcripts were up-regulated due to the deletion
of GnT-Va. Increased gene expression of GnT-III may
account for the enhanced E-PHA binding in GnT-Va null
MEFs, indicating for the ﬁrst time that the opposing expres-
sion pattern of GnT-Va and GnT-III glycan products may
be due to regulation of these enzymes at the level of transcrip-
tion. This result is further supported by our recent observation
that increased gene expression of GnT-Va was accompanied
by reduced GnT-III gene expression in Her-2/neu-induced
mouse mammary tumor tissue (unpublished data), indicating
that these two genes might be regulated by an opposing
manner.Poly-N-acetyllactosamine is synthesized preferentially on N-
glycans expressing the b(1,6) branch. In our study, we found
that poly-N-acetyllactosamine showed a concomitant de-
creased expression when N-linked b(1,6) branches were elimi-
nated by knockout of GnT-Va. Although some of the
transcript levels of glycosyltransferases which are involved in
the biosynthesis of poly-N-acetyllactosamine were extremely
down-regulated, enhanced gene expression within this family
was also observed. Reduced expression of poly-N-acetyllactos-
amine, detected by DSA binding likely resulted, at least in
part, from altered gene expression of relevant glycosyltransfer-
ases.
Sialylation is another important modiﬁcation of glycopro-
teins and aberrant sialylation has been reported to relate to
the progression of several types of human tumors [22,23]. In
mammalian cells, six a(2,3) sialyltransferases (ST3Gal I–VI)
have been identiﬁed. Down-regulation of ST3Gal IV and VI
was observed in GnT-Va knockout MEFs, which likely ac-
counts for the signiﬁcant decrease in expression of a(2,3) sialy-
lation detected by MAA binding.
The transcripts for ST6GalTs, forming a(2,6) sialylation
structures, were signiﬁcantly up-regulated in GnT-Va deﬁcient
MEFs, which is consistent with the observed increased expres-
sion of a(2,6) sialylation, detected by SNA binding, suggesting
that elimination of GnT-Va expression negatively regulate the
formation of a(2,6) sialylation. This hypothesis was further
supported by our recent observations that knockdown of
GnT-Va caused increased a(2,6) sialylation on EGFR [8],
and enhanced gene expression of GnT-Va in Her-2/neu in-
duced mammary tumor tissue was accompanied by down-reg-
ulation of ST6GalT (unpublished data). Indeed, a(2,6)
sialylation of cell surface N-glycans was reported to inhibit tu-
mor formation in vivo [24] and attenuate the neoplastic pheno-
type of human colon cancer cells [22], indicating an opposing
role of increased ST6GalT, compared to increased GnT-Va,
in mediating tumorigenesis.
Polysialic acid (PSA) is another post-translational modiﬁca-
tion consisting of a homopolymer of a(2,8) linked sialic acid,
which plays a critical role in regulating neural development
and tumor progression [15]. Dramatically, concomitant
with a marked reduction of polysialylation detected by anti-
poly-sialylation antibody, we found that the transcript levels
of ST8Sia II/STX were signiﬁcantly reduced after deletion of
GnT-Va, while the level of ST8Sia IV/PST was very low.
N-CAM is a major carrier of PSA [25], and the presence of
PSA attenuates the adhesive property of N-CAM and in-
creases cell motility. Decreased expression of PSA caused by
down-regulation of ST8Sia II/STX transcripts after deletion
of GnT-Va may, therefore, lead to a phenotype with increased
cell adhesive properties and decreased cell motility. This
hypothesis is consistent with inhibited cell growth and support-
ive of previous ﬁndings that GnT-Va null MEFs and tumor
cells showed decreased cell motility [7,10].
Intriguingly, deletion of GnT-Va also aﬀected the transcript
expression level of core2GnT-I, a Golgi enzyme that catalyzes
the formation of b(1,6) branched structure attached to O-Gal-
NAc [18]. This enzyme was found to be expressed in the
developing mouse embryo and was closely correlated with
vessel invasion and depth of invasion of several human can-
cers.
Among 15 identiﬁed mammalian galectins, Gal-1 and -3
have been intensively studied for their roles in regulating cell
Fig. 3. Deletion of GnT-Va resulted in altered gene expression of glycosyltransferases. (A) Expression of several N-acetylglucsoaminyltransferases
(gnt). (B) Relative transcript levels of b4-galactosyltransferases (B4galt1-7) and b3-N-acetylglucosaminyltransferases (B3gnt1-8). (C) Relative
transcript levels of a2,3-sialyltransferases (ST3Gal I-VI), a2,6-sialyltransferases (ST6Gal I-II) and a2,8-sialyltransferases (ST8Sia I-VI). (D) Relative
transcript levels of core2N-acetylglucosaminyltransferase (Gcnt1), I-branching N-acetylglucosaminyltransferase (Gcnt2), mucin-type N-acetylglu-
cosaminyltransferase (Gcnt3). Data expressed as ‘‘relative transcript abundance’’ are plotted on a log scale for each gene assayed. Error bars
represent one standard deviation from the mean of triplicate values.
H.-B. Guo et al. / FEBS Letters 582 (2008) 527–535 533proliferation, apoptosis and tumor progression [26,27]. In our
study, we found that knockout of GnT-Va also resulted in in-
creased transcript levels of Gal-1 and Gal-3, accompanied by
increased protein expression detected by Western blotting.
Gal-9 was originally identiﬁed as a tumor antigen and is asso-
ciated with suppression of cell growth and induces apoptosis.
Increased Gal-1, -3 and -9 may be related to the inhibited cell
growth and survival of GnT-Va null MEFs observed in our
study. Of note, gene expression of Gal-1 was inhibited in
Her-2/neu-induced mouse mammary tumor tissue and cells
[28], suggesting that up-regulated gene expression of Gal-1
after deletion of GnT-Va may function in GnT-Va-mediated
mammary tumor progression[5]. Among the down-regulated
galectins, Gal-8 showed relatively higher expression in GnT-
Va null MEFs. This galectin has been reported to be a matrix
protein that can positively or negatively modulate cell adhe-
sion [29] and its down-regulation may, therefore, contribute
to some of the altered cell adhesion properties caused by dele-
tion of GnT-Va in MEFs [10].
The altered gene expression of several groups of glycosyl-
transferases and galectins caused by genetic disruption of
one speciﬁc glycosyltransferase has not as yet been reported.
Studies have shown that knockout or knockdown of GnT-
Va caused aberrant N-glycosylation of surface growth factorreceptors and are associated with altered signaling pathway
mediated by these receptors [7,8,10,30]. These aberrant signals
might up- or down-regulate gene expression patterns of some
glycosyltransferases and glycan-recognition proteins. We did
ﬁnd that knockout of GnT-Va in MEFs caused increased gene
expression of b1 integrin [10]. Furthermore, increased gene
expression of some integrins was also observed in SH-SY5Y
cells after GnT-Vb knockdown by siRNA [31]. These ﬁndings
suggest that the expression level of GnT-Va indeed played a
role in regulating expression of other proteins. In addition, it
is believed that the galectin binding increases if galactose is at-
tached to an N-acetylglucosamine of glycoproteins on the cell
surface forming N-acetyllactosamine [32]. A recent paper
shows that galectins cross-link glycoproteins on the cell surface
with avidities dependent on N-glycan structure and number
[30]. Knockout of GnT-Va caused reduced expression of
poly-N-acetyllactosamine structures, preferred ligands of the
galectins, which could possibly render feedback regulation on
the expression of some galectins, causing increased gene
expression of Gal-1 and Gal-3. In conclusion, our results sug-
gest possible coordination between GnT-Va expression and the
expression of several glycosyltransferases and lectins, although
the mechanisms that result in this coordination are, as yet, un-
known.
Fig. 4. Deletion of GnT-Va resulted in altered galectins gene expression. (A) Relative transcript levels for galectins: galectin 1 (Lgals1), galectin 2
(Lgals2), galectin 3 (Lgals3), galectin 4 (Lgals4), galectin 6 (Lgals6), galectin 7 (Lgals7), galectin 8 (Lgals8), galectin 9 (Lgals9) and galectin 12
(Lgals12). (B) The expression levels of galectins-1 and -3 and ERK in MEFs were detected by immunoblotting using the respective antibodies (left
panel). Relative levels of gal-1 and -3 were calculated by band intensity of gal-1 or gal-3/intensity of ERK, and data represent the mean (±S.D.) of
three independent experiments (right panel).
Table 3
Altered gene expression proﬁle of galectins in GnT-Va null MEFs
Gene WTa KOa Ratio (WT/KO)
Lgals1 3.569301 7.843389 0.455071
Lgals2 0.000560 0.000838 0.668573
Lgals3 0.027261 0.062521 0.436029
Lgals4 0.000433 0.000118 3.661759
Lgals6 0.000673 0.000227 2.963587
Lgals7 0.000048 0.000038 1.282823
Lgals8 0.008210 0.005495 1.494213
Lgals9 0.008108 0.031355 0.258580
Lgals12 0.000001 0.000001 1.000000
0.000001 = below the level of detection.
The ratio is a simple division of the data for WT and KO for a speciﬁc
gene.
aRelative transcript abundance (as described in Section 2).
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